TOPLINE:
METHODOLOGY:
- Cervical cancer is the fourth most common cancer among women worldwide.
- Programs to provide Cervarix, a bivalent vaccine, began in the United Kingdom in 2007.
- After the initiation of the programs, administering the vaccine became part of routine care for girls starting at age 12 years.
- Researchers collected data in 2020 from 447,845 women born between 1988 and 1996 from the Scottish cervical cancer screening system to assess the efficacy of Cervarix in lowering rates of cervical cancer.
- They correlated the rate of cervical cancer per 100,000 person-years with data on women regarding vaccination status, age when vaccinated, and deprivation in areas like income, housing, and health.
TAKEAWAY:
- No cases of cervical cancer were found among women who were immunized at ages 12 or 13 years, no matter how many doses they received.
- Women who were immunized between ages 14 and 18 years and received three doses had fewer instances of cervical cancer compared with unvaccinated women regardless of deprivation status (3.2 cases per 100,00 women vs 8.4 cases per 100,000).
IN PRACTICE:
“Continued participation in screening and monitoring of outcomes is required, however, to assess the effects of changes in vaccines used and dosage schedules since the start of vaccination in Scotland in 2008 and the longevity of protection the vaccines offer.”
SOURCE:
The study was led by Timothy J. Palmer, PhD, Scottish Clinical Lead for Cervical Screening at Public Health Scotland.
LIMITATIONS:
Only 14,645 women had received just one or two doses, which may have affected the statistical analysis.
DISCLOSURES:
The study was funded by Public Health Scotland. A coauthor reports attending an advisory board meeting for HOLOGIC and Vaccitech. Her institution received research funding or gratis support funding from Cepheid, Euroimmun, GeneFirst, SelfScreen, Hiantis, Seegene, Roche, Hologic, and Vaccitech in the past 3 years.
A version of this article appeared on Medscape.com.